Lead Sponsor

Sanofi

Collaborators

Age

40 - 85 years

Sex

ALL

Healthy Volunteers

No

•\- Patients with COPD who completed the treatment period in a previous itepekimab COPD Phase 3 clinical study (ie, EFC16750 or EFC16819) and for which an end-of-treatment (EOT) visit occurred no later than 3 days before the enrolment visit of this study.

•Diagnosis of a malignancy during parent study, except a squamous or basal cell carcinoma of the skin
•Any opportunistic infection during the parent study, such as tuberculosis (TB) or other infections whose nature or course may suggest an immunocompromised status
•Anaphylactic reactions or systemic allergic reactions that are related to IMP and require treatment during the parent study
•Any situation that led to a permanent premature IMP discontinuation in parent trials
•The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.